Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
Summer Street must have missed this part of the call:
.
.
In summary, the 171 trial met the primary efficacy endpoint of non-inferior reduction in A1c when comparing AFREZZA -Gen2 to insulin aspart as well as the primary safety endpoint of showing a comparable mean change in FEV1 over the treatment period between the Gen2 and the MedTone treatment groups.
